StealthX™ Therapeutic Delivery Platform
Multiple (Undisclosed)
PreclinicalPlatform in development for oligonucleotide, protein, and small molecule delivery
Key Facts
Indication
Multiple (Undisclosed)
Phase
Preclinical
Status
Platform in development for oligonucleotide, protein, and small molecule delivery
Company
About Capricor Therapeutics
Capricor Therapeutics is dedicated to advancing a new class of medicines using its core expertise in cardiosphere-derived cells (CDCs) and exosome science. The company is on the cusp of a potential regulatory milestone with Deramiocel for DMD, supported by positive late-breaking HOPE-3 trial data. Beyond its lead program, Capricor is building a broader pipeline through its StealthX™ platform, targeting the delivery of oligonucleotides, proteins, and small molecules, positioning it at the forefront of precision-engineered exosome therapeutics.
View full company profile